Project Grant R01HL182844
Award Date 7/15/26
Completion Date 4/30/31
Dollars Obligated $733K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Shreveport, LA 71130, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $737,242 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage one-carbon metabolism in atherosclerotic plaque stability. The recipient will conduct research examining serine hydroxymethyltransferase 2 (SHMT2)-dependent one-carbon metabolism in macrophages and its role in maintaining plaque stability and preventing atherosclerotic...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $737,455 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate provisional matrix-binding integrins as therapeutic targets in advanced atherosclerosis. The research examines how wound-associated extracellular matrix proteins promote atherogenic inflammation and plaque vulnerability, and tests whether combined deletion of α5 and αV integrins...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $111,111 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms linking endoplasmic reticulum stress, lipid accumulation, and vascular inflammation in atherosclerosis. The research defines how the NCK1 adaptor protein integrates mechanical and metabolic stress to drive endothelial dysfunction. Aim 1 investigates how NCK1...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $842,500 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of cell-specific programmed death-ligand-1 (PD-L1) in cardiac pathophysiology following ischemic injury and in immune checkpoint inhibitor-mediated cardiotoxicity. The research examines how PD-L1 expression in fibroblasts and myeloid cells regulates repair and...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $248,679 on February 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the nuclear protein HMGXB4 in occlusive vascular diseases. The research examines vascular smooth muscle cell phenotypic modulation in restenosis and atherosclerosis. The project focuses on elucidating how HMGXB4 regulates the transition from contractile to...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $108,648 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on novel mechanisms of lung cancer-associated thrombosis. The funded research investigates venous thromboembolism in lung cancer patients, with focus on the role of phosphoglycerate kinase 1 (PGK1) in neutrophil-mediated deep vein thrombosis. The project uses...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Agricultural Center $514,318 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to investigate the functional role of myofibroblast contractile machinery in cardiac repair following myocardial infarction. The research examines how cardiac myofibroblasts respond after myocardial infarction through three coordinated aims. Aim 1 employs mouse lines with inducible fibroblast-specific...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,500 on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage biology in atherosclerosis and atherosclerosis-related cardiometabolic disease. The award funds a comprehensive program exploring the role of macrophage efferocytosis and resolution cycles in promoting fibrous cap thickening in atherosclerotic plaques and...
- The National Heart, Lung, and Blood Institute awarded The Administrators of Tulane Educational Fund (Tulane University) $499,736 in Project Grant funding on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating mechanisms of cholesterol-induced lymphatic dysfunction and whether GLP-1R agonism can improve lymphatic function in obesity and metabolic syndrome. The work addresses lymphedema, a chronic disease affecting more...
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...